MFN reinforces the worst incentives in 340B, shifts costs to patients and employers, and threatens the long-term health of both public programs and private enterprise.

A new report on the 340B Drug Pricing Program released Thursday by the chairman of the Senate Health, Education, Labor and Pensions Committee calls for “much-needed” legislative reforms around transparency and oversight of the contentious discount program.

340B Health and two safety-net hospitals want to help the government prove that drugmakers are required to give discounts on 340B drugs at the point of sale.

During my recent Drug Channels Outlook 2025 video webinar, I tackled a wide range of crucial topics—including the controversial 340B Drug Pricing Program. As I explain in this video excerpt, we may finally see reform of this rapidly expanding program.

What’s more, implementing the Inflation Reduction Act will disrupt the current operations of the 340B program—and could shift program oversight from Health Resources and Services Administration to the Centers for Medicare & Medicaid Services.

It’s time to pay attention to the money behind the 340B curtain.

Minnesota just released the industry‘s first ever mandated financial report on the 340B Drug Pricing Program. Below, I do a wicked deep dive into the data and highlight crucial implications about spending, profits, pharmacies, plans, patients, program integrity, and more.

Bristol-Myers Squibb has become the latest drugmaker in the US to file a legal challenge to a block on a drug rebate model opposed by a Health and Human Services (HHS) department.

French drugmaker Sanofi plans to change its policy on how it gives discounts to certain U.S. hospitals that serve low-income and uninsured patients, the company said on Friday.